Your browser doesn't support javascript.
loading
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Allanore, Yannick; Wung, Peter; Soubrane, Christina; Esperet, Corinne; Marrache, Frederic; Bejuit, Raphael; Lahmar, Amel; Khanna, Dinesh; Denton, Christopher P.
Afiliación
  • Allanore Y; Rheumatology Department, Cochin Hospital, Paris Descartes University, Paris, France yannick.allanore@cch.aphp.fr.
  • Wung P; Sanofi R&D, Bridgewater, New Jersey, USA.
  • Soubrane C; Sanofi R&D, Chilly-Mazarin, France.
  • Esperet C; Sanofi R&D, Chilly-Mazarin, France.
  • Marrache F; Immunology and Inflammation, Sanofi R&D, Chilly-Mazarin, France.
  • Bejuit R; Statistics and Programming, Sanofi, Chilly-Mazarin, France.
  • Lahmar A; Global Safety, Sanofi R&D, Bridgewater, New Jersey, USA.
  • Khanna D; Rheumatology Clinic, University of Michigan, Ann Arbor, Michigan, USA.
  • Denton CP; Centre for Rheumatology and and Connective Tissue Diseases, University College London Division of Medicine, London, UK.
Ann Rheum Dis ; 79(12): 1600-1607, 2020 12.
Article en En | MEDLINE | ID: mdl-32963047

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interleucina-4 / Anticuerpos Biespecíficos / Interleucina-13 / Esclerodermia Difusa / Inmunosupresores Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2020 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interleucina-4 / Anticuerpos Biespecíficos / Interleucina-13 / Esclerodermia Difusa / Inmunosupresores Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2020 Tipo del documento: Article País de afiliación: Francia